Clearmind advances CMND-100 alcohol use disorder trial into patient testing after Phase I safety readout

Reuters2026/08/06 13:26

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Clearmind Medicine’s DSMB cleared its FDA-regulated Phase I/II trial of CMND-100 to move into Parts B and C.
Results from Part A have already been reviewed, supporting progression based on a favorable safety and tolerability profile in healthy participants.
Part B will test CMND-100 in moderate to severe alcohol use disorder patients for the first time, targeting early signs of reduced drinking and craving.
Part C will run in parallel in healthy participants to further assess safety and tolerability during a multi-day dosing schedule.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Clearmind advances CMND-100 alcohol use disorder trial into patient testing after Phase I safety readout

You may also like

Crypto prices